Implications and considerations of V179D mutation in a patient with HIV treated with cabotegravir/rilpivirine: A case report and mini‑review of the literature

Spampinato,Serena; Marino,Andrea; Celesia,Benedetto Maurizio; Venanzi Rullo,Emmanuele; Condorelli,Fabrizio; Cacopardo,Bruno; Nunnari,Giuseppe

doi:10.3892/wasj.2024.234

Implications and considerations of V179D mutation in a patient with HIV treated with cabotegravir/rilpivirine: A case report and mini‑review of the literature

Authors:
- Serena Spampinato
- Andrea Marino
- Benedetto Maurizio Celesia
- Emmanuele Venanzi Rullo
- Fabrizio Condorelli
- Bruno Cacopardo
- Giuseppe Nunnari
View Affiliations

Affiliations: Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, ARNAS Garibaldi Hospital, I‑95122 Catania, Italy, Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, I‑98124 Messina, Italy, Department of Pharmacological Sciences, Università del Piemonte Orientale ‘A. Avogadro’, I‑28100 Novara, Italy
Published online on: March 4, 2024 https://doi.org/10.3892/wasj.2024.234
Article Number: 19
Copyright : © Spampinato et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The management of antiretroviral therapy is intricately associated with the evaluation of the viral genetic profile, a process in which infectious disease specialists play a pivotal role in both the selection and fine‑tuning of treatment protocols. The V179D aminoacidic variation within the reverse transcriptase of the human immunodeficiency virus (HIV), while not considered among major mutations, carries the potential to exert a notable effect on resistance to antiretroviral agents. Notably, this influence extends specifically to the class of non‑nucleoside reverse transcriptase inhibitors, suggesting that the presence of the V179D mutation may diminish the susceptibility of the virus to certain antiretroviral drugs within this classification. The present study describes the case of a patient which delineates the management trajectory of an HIV‑positive individual, commencing from the initial diagnosis in November, 2017. A genotypic resistance test revealed the presence of the V179D mutation. Of note, notwithstanding the existence of this mutation, the patient underwent a transition to a cabotegravir and rilpivirine injectable combination regimen, resulting in a favorable treatment response characterized by comprehensive and sustained viral suppression, coupled with enhancements in the immunological profile. The case described herein underscores the critical significance of a tailored approach in the management of HIV, wherein therapeutic strategies are adeptly tailored to the unique exigencies of people living with HIV.

View Figures

View References

1	Yeo JY, Goh GR, Su TTT and Gan SKE: The determination of HIV-1 RT mutation rate, its possible allosteric effects, and its implications on drug resistance. Viruses. 12(297)2020.PubMed/NCBI View Article : Google Scholar
2	Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, et al: Low-Frequency HIV-1 drug resistance mutations and risk of NNRTI-Based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA. 305:1327–1335. 2015.PubMed/NCBI View Article : Google Scholar
3	Fisicaro V, Campanella E, Marino A, Guarneri A, Franzò A, Pistarà E, Spampinato S, Bandiera A, Boscia V, Celesia BM, et al: Laryngeal leishmaniasis in a HIV positive Patient: A case report and review of the literature. World Acad Sci J 5: doi:10.3892/WASJ.2023.201, 2023.
4	Soltani S, Farahani A, Zebardast A, Dowran R, Zandi M, Rafat Z, Sasani E, Zarandi B, Fallahy MP and Didehdar M: Human immunodeficiency virus and Candida albicans co-infection in Iran: A systematic review. HIV AIDS Rev. 22:181–188. 2023.
5	Holtz CM and Mansky LM: Variation of HIV-1 mutation spectra among cell types. J Virol. 87:5296–5299. 2013.PubMed/NCBI View Article : Google Scholar
6	Chen R, Yokoyama M, Sato H, Reilly C and Mansky LM: Human immunodeficiency virus mutagenesis during antiviral therapy: Impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies. J Virol. 79:12045–12057. 2005.PubMed/NCBI View Article : Google Scholar
7	Gupta S, Lataillade M, Kyriakides TC, Chiarella J, John EPS, Webb S, Moreno EA, Simen BB and Kozal MJ: Low-Frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects. Viruses. 6:3428–3437. 2014.PubMed/NCBI View Article : Google Scholar
8	Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR and Kuritzkes DR: Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS. 26:185–192. 2012.PubMed/NCBI View Article : Google Scholar
9	Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Gigue F, Meyer WA III, Johnson VA, Fiscus SA, D'Aquila RT, et al: Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 201:662–671. 2010.PubMed/NCBI View Article : Google Scholar
10	Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, Shafer RW and Richman DD: 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 27:111–121. 2019.PubMed/NCBI
11	Jiao L, Li H, Li L, Zhuang D, Liu Y, Bao Z, Liu S and Li J: Impact of novel resistance profiles in HIV-1 reverse transcriptase on phenotypic resistance to NVP. AIDS Res Treat. 2012(637263)2012.PubMed/NCBI View Article : Google Scholar
12	2022 Update of HIV Drug Resistance Mutations in HIV-1 Is Now Available Online-IAS-USA Available online: https://www.iasusa.org/2022/09/23/2022-update-of-hiv-drug-resistance-mutations-now-available/ (accessed on 26 December 2023).
13	Wang Z, Zhang M, Wang J, Liu L, Chen J, Zhang R, Tang Y, Shen Y, Qi T, Song W, et al: Efficacy of Efavirenz-Based regimen in Antiretroviral-Naïve PAtients with HIV-1 V179D/E mutations in Shanghai, China. Infect Dis Ther. 12:245–255. 2023.PubMed/NCBI View Article : Google Scholar
14	Liu Y, Zhang Y, Li H, Wang X, Jia L, Han J, Li T, Li J and Li L: Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains. BMC Infect Dis. 20(313)2020.PubMed/NCBI View Article : Google Scholar
15	Obasa AE, Mikasi SG, Brado D, Cloete R, Singh K, Neogi U and Jacobs GB: Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa. Front Microbiol. 11(438)2020.PubMed/NCBI View Article : Google Scholar
16	SeyedAlinaghi SA, Afsahi AM, Moradi A, Parmoon Z, Habibi P, Mirzapour P, Dashti M, Ghasemzadeh A, Karimi E, Sanaati F, et al: Current ART, determinants for virologic failure and implications for HIV drug resistance: An umbrella review. AIDS Res Ther. 20(74)2023.PubMed/NCBI View Article : Google Scholar
17	Mittelholzer C and Klimkait T: Advances in molecular genetics enabling studies of highly pathogenic RNA viruses. Viruses. 14(2682)2022.PubMed/NCBI View Article : Google Scholar
18	Krishnan S, Lippincott CK, Bjerrum S, Rivera MB and Shah M: A national HIV provider survey of antiretroviral therapy preferences for management of treatment-naive and experienced individuals with drug resistance. Open Forum Infect Dis. 10(ofad541)2023.PubMed/NCBI View Article : Google Scholar
19	Celesia BM, Marino A, Del Vecchio RF, Bruno R, Palermo F, Gussio M, Nunnari G and Cacopardo B: Is it safe and cost saving to defer the CD4+ cell count monitoring in stable patients on ART with more than 350 or 500 cells/ΜL? Mediterr J Hematol Infect Dis. 11(e2019063)2019.PubMed/NCBI View Article : Google Scholar
20	Marino A, Zafarana G, Ceccarelli M, Cosentino F, Moscatt V, Bruno G, Bruno R, Benanti F, Cacopardo B and Celesia BM: Immunological and clinical impact of DAA-mediated HCV eradication in a cohort of HIV/HCV coinfected patients: Monocentric Italian experience. Diagnostics (Basel). 11(2336)2021.PubMed/NCBI View Article : Google Scholar
21	Marino A, Caltabiano E, Zagami A, Onorante A, Zappalà C, Locatelli ME, Pampaloni A, Scuderi D, Bruno R and Cacopardo B: Rapid emergence of cryptococcal fungemia, mycobacterium chelonae vertebral osteomyelitis and gastro intestinal stromal tumor in a young HIV late presenter: A case report. BMC Infect Dis. 18(693)2018.PubMed/NCBI View Article : Google Scholar
22	Celesia BM, Marino A, Borracino S, Arcadipane AF, Pantò G, Gussio M, Coniglio S, Pennisi A, Cacopardo B and Panarello G: Successful extracorporeal membrane oxygenation treatment in an acquired immune deficiency syndrome (AIDS) patient with acute respiratory distress syndrome (ARDS) complicating pneumocystis jirovecii pneumonia: A challenging case. Am J Case Rep. 21(e919570)2020.PubMed/NCBI View Article : Google Scholar
23	Spampinato S, Saia AG, Russotto Y, Micali C, Marino A, Ceccarelli M, Rullo E, Pellicanò GF and Nunnari G: Real-life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine in HIV-infected individuals. Infectious Diseases and Tropical Medicine. 9(e1207)2023.
24	Cosentino F, Marino A, Anile L, Moscatt V, Gussio M, Boscia V, Bruno R, Nunnari G, Pulvirenti A, Privitera GF, et al: Long-term survivors in a cohort of people living with HIV diagnosed between 1985 and 1994: Predictive factors associated with more than 25 years of survival. Infect Dis Rep. 15:70–83. 2023.PubMed/NCBI View Article : Google Scholar
25	Rhee SY, Kassaye SG, Jordan MR, Kouamou V, Katzenstein D and Shafer RW: Public availability of HIV-1 drug resistance sequence and treatment data: A systematic review. Lancet Microbe. 3:e392–e398. 2022.PubMed/NCBI View Article : Google Scholar